CL2011000420A1 - Ester ter-butilico del acido [6-(5-etoximetoxi-benzofuran-2-il)-2-nitro-piridin-3-il]-metil-carbamico; proceso de preparacion; ester ter-butilico del acido [5-(5-etoximetoxi-benzofuran-2-il)-6-nitro-piridin-2-il]-metilcarbamico; y su uso como precursor para preparar un compuesto marcado. - Google Patents

Ester ter-butilico del acido [6-(5-etoximetoxi-benzofuran-2-il)-2-nitro-piridin-3-il]-metil-carbamico; proceso de preparacion; ester ter-butilico del acido [5-(5-etoximetoxi-benzofuran-2-il)-6-nitro-piridin-2-il]-metilcarbamico; y su uso como precursor para preparar un compuesto marcado.

Info

Publication number
CL2011000420A1
CL2011000420A1 CL2011000420A CL2011000420A CL2011000420A1 CL 2011000420 A1 CL2011000420 A1 CL 2011000420A1 CL 2011000420 A CL2011000420 A CL 2011000420A CL 2011000420 A CL2011000420 A CL 2011000420A CL 2011000420 A1 CL2011000420 A1 CL 2011000420A1
Authority
CL
Chile
Prior art keywords
ethoxymethoxy
benzofuran
pyridin
nitro
butyl ester
Prior art date
Application number
CL2011000420A
Other languages
English (en)
Inventor
Seth Bjork
Vern Delisser
Peter Johnstrom
Nils Anders Nilsson
Katinka Ruda
Per Magnus Schou
Britt-Marie Swahn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2011000420A1 publication Critical patent/CL2011000420A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Ester terbutílico del ácido [6-(5-etoximetoxi-benzofuran-2-il)-2-nitro-piridin-3-il]-metil-carbamico, y su forma cristalina; proceso de preparación; ester terbutílico del ácido [5-(5-etoximetoxi-benzofuran-2-il)-6-nitro-piridin-2-il]-metil-carbamico, y su forma cristalina; y su uso como precursor para preparar un compuesto marcado.
CL2011000420A 2008-08-29 2011-02-25 Ester ter-butilico del acido [6-(5-etoximetoxi-benzofuran-2-il)-2-nitro-piridin-3-il]-metil-carbamico; proceso de preparacion; ester ter-butilico del acido [5-(5-etoximetoxi-benzofuran-2-il)-6-nitro-piridin-2-il]-metilcarbamico; y su uso como precursor para preparar un compuesto marcado. CL2011000420A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9285108P 2008-08-29 2008-08-29

Publications (1)

Publication Number Publication Date
CL2011000420A1 true CL2011000420A1 (es) 2011-07-15

Family

ID=41721733

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000420A CL2011000420A1 (es) 2008-08-29 2011-02-25 Ester ter-butilico del acido [6-(5-etoximetoxi-benzofuran-2-il)-2-nitro-piridin-3-il]-metil-carbamico; proceso de preparacion; ester ter-butilico del acido [5-(5-etoximetoxi-benzofuran-2-il)-6-nitro-piridin-2-il]-metilcarbamico; y su uso como precursor para preparar un compuesto marcado.

Country Status (22)

Country Link
US (3) US8193363B2 (es)
EP (1) EP2328891B1 (es)
JP (1) JP5613669B2 (es)
KR (1) KR101648848B1 (es)
CN (3) CN102197036B (es)
AR (2) AR073230A1 (es)
AU (1) AU2009286176B2 (es)
BR (1) BRPI0917147B8 (es)
CA (1) CA2735497C (es)
CL (1) CL2011000420A1 (es)
CO (1) CO6341628A2 (es)
EA (1) EA019093B1 (es)
EC (1) ECSP11010850A (es)
ES (1) ES2627769T3 (es)
IL (1) IL211188A0 (es)
MX (1) MX2011001918A (es)
NZ (1) NZ591446A (es)
PE (1) PE20110393A1 (es)
TW (1) TW201014848A (es)
UY (1) UY32076A (es)
WO (1) WO2010024769A1 (es)
ZA (1) ZA201102284B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193363B2 (en) * 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
JP5825608B2 (ja) * 2010-08-06 2015-12-02 国立大学法人京都大学 ピリジルベンゾフラン誘導体
US10098859B2 (en) 2012-09-05 2018-10-16 Amri Ssci, Llc Cocrystals of p-coumaric acid
KR20190136125A (ko) 2012-12-21 2019-12-09 국립연구개발법인 양자과학기술연구개발기구 뇌 안에 축적된 타우 단백질을 이미징하기 위한 신규한 화합물
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
KR20180113975A (ko) * 2015-11-20 2018-10-17 나비디아 바이오파마슈티컬즈, 인크. 2-헤테로아릴 치환된 벤조푸란에 대한 제제
JP7293343B2 (ja) 2018-05-09 2023-06-19 アプリノイア セラピューティクス リミテッド ヘテロアリール化合物及びその使用
CA3161455A1 (en) 2019-11-13 2021-05-20 Aprinoia Therapeutics Limited Compounds for degrading tau protein aggregates and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1041525A (en) 1964-11-11 1966-09-07 Belge Produits Chimiques Sa Benzofuran derivatives and processes for preparing the same
JPH09507071A (ja) 1993-12-21 1997-07-15 イーライ・リリー・アンド・カンパニー アミロイド原性ペプチドに関連した状態を治療又は予防する方法
MXPA02003740A (es) * 1999-10-15 2002-09-30 Hoffmann La Roche Derivados de benzodiazepina.
FR2800069A1 (fr) * 1999-10-22 2001-04-27 Centre Nat Rech Scient 3-amino-2,2-di-c-alkyl-1,4-butyrolactones et 1,4- thiobutyrolactones n-substituees utiles comme stimulant de l'activite de l'acide gamma-aminobutyrique et leur procede de preparation
JP2004520347A (ja) 2001-01-15 2004-07-08 グラクソ　グループ　リミテッド Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
JP4307001B2 (ja) 2001-03-14 2009-08-05 キヤノン株式会社 金属配位化合物、電界発光素子及び表示装置
GB0130305D0 (en) 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
AU2003258022A1 (en) 2002-08-02 2004-02-23 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
WO2004100998A2 (en) * 2003-05-07 2004-11-25 General Electric Company Compositions and methods for non-invasive imaging of soluble beta-amyloid
US20040223912A1 (en) * 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
EP1644365A2 (en) 2003-07-02 2006-04-12 Biofocus Discovery Ltd Pyrazine and pyridine derivatives as rho kinase inhibitors
AU2005274927B2 (en) * 2004-07-15 2011-11-03 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
MX2007011234A (es) * 2005-03-14 2007-11-12 Transtech Pharma Inc Derivados de benzazol, composiciones y metodos de uso en la forma de inhibidores de b-secretasa.
EP2386554A1 (en) 2005-07-04 2011-11-16 High Point Pharmaceuticals, LLC Compounds active at the histamine H3 receptor
EP1945622B1 (en) * 2005-10-11 2011-12-28 University of Pittsburgh - Of the Commonwealth System of Higher Education Isotopically-labeled benzofuran compounds as imagingagents for amyloidogenic proteins
TW200736252A (en) * 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
MX2009006003A (es) * 2006-12-05 2009-06-17 Univ Nagasaki Composicion que contiene derivados de aurona con fines de diagnostico.
JP4328820B2 (ja) 2007-01-10 2009-09-09 田辺三菱製薬株式会社 医薬組成物
TW200901998A (en) * 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
US8193363B2 (en) 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits

Also Published As

Publication number Publication date
NZ591446A (en) 2012-08-31
JP2012501324A (ja) 2012-01-19
PE20110393A1 (es) 2011-07-15
US20140296534A1 (en) 2014-10-02
IL211188A0 (en) 2011-04-28
MX2011001918A (es) 2011-03-24
JP5613669B2 (ja) 2014-10-29
US9309267B2 (en) 2016-04-12
AR114029A2 (es) 2020-07-15
CN102197036B (zh) 2014-12-10
BRPI0917147A2 (pt) 2015-11-17
EP2328891B1 (en) 2017-04-05
CO6341628A2 (es) 2011-11-21
CN104447710A (zh) 2015-03-25
US20120264943A1 (en) 2012-10-18
BRPI0917147B1 (pt) 2020-09-15
TW201014848A (en) 2010-04-16
US8653274B2 (en) 2014-02-18
KR101648848B1 (ko) 2016-08-17
CA2735497A1 (en) 2010-03-04
EP2328891A4 (en) 2012-07-04
KR20110045023A (ko) 2011-05-03
AR073230A1 (es) 2010-10-20
US8193363B2 (en) 2012-06-05
US20100056796A1 (en) 2010-03-04
CN104478862B (zh) 2017-05-24
AU2009286176A1 (en) 2010-03-04
UY32076A (es) 2010-03-26
EP2328891A1 (en) 2011-06-08
CN104478862A (zh) 2015-04-01
EA019093B1 (ru) 2014-01-30
WO2010024769A1 (en) 2010-03-04
ECSP11010850A (es) 2011-03-31
EA201100267A1 (ru) 2011-10-31
ES2627769T3 (es) 2017-07-31
CA2735497C (en) 2016-07-19
CN102197036A (zh) 2011-09-21
ZA201102284B (en) 2012-09-26
AU2009286176B2 (en) 2012-04-26
BRPI0917147B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
EP2663397A4 (en) Production of biochar absorbent from anaerobic digestate
MX393128B (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas
CL2016000346A1 (es) Proceso para preparar compuestos intermediarios en la preparación de pirazolil pirrol pirimidinas.
PH12014500813A1 (en) Novel [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor
EP3778606A3 (en) Condensed imidazolylimidazoles as antiviral compounds
GT201300078A (es) Proceso para la preparacion de inhibidores de pan-cdk de la formula ( i ), e intermediarios de la preparacion
ZA201403880B (en) Processes fro the conversion of biomass to oxygenated organic compound, apparatus therefore and compositions produced thereby
CO6351724A2 (es) Inhibidores de cmet
AR062148A1 (es) Proceso quimico para la preparacion de intermediarios
EP2665697A2 (en) Process for the hydration of mixed butenes to produce mixed alcohols
BR112013006066A2 (pt) método para produzir etanol utilizando biomassa celulósica como matéria-prima
CR20130515A (es) Imidazopiridazinas como inhibidores de quinasa akt
PH12014501026A1 (en) [1, 2, 3]triazolo[4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 agonists
BRPI0918142A2 (pt) composição farmaclógica tópica, seu método de preparação, bem como uso da forma de ácido livre de ácido 2-(4-isobutifilfenil)prpiônico
CL2013003191A1 (es) Uso de compuestos derivados de acidos carboxilicos de trifluorometil-benzotiofenos, en méetodos para promover el crecimiento de plantas.
EA201270280A1 (ru) Соединения пиримидина в качестве ингибиторов при лечении туберкулеза
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
MX344911B (es) Compuestos de eter amido-piridilico y composiciones y su uso contra parasitos.
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
AR089381A1 (es) Fucosa como depresor del punto de congelacion en composiciones nutricionales congeladas
DOP2015000007A (es) Métodos para preparar triazolopiridinas sutituidas
EP2733204A4 (en) METHOD FOR THE PRODUCTION OF A PLURIPOTENTIAL CELL WITH FERMENTABLE BACTERIUM
CL2014000212A1 (es) Uso de sacarosa enzimaticamente invertida como dispersante para aglutinante mineral; un dispersante; una composicion aglutinante; un cuerpo moldeado; y un metodo para preparar dicha composicion.
MX2013002656A (es) Nuevo proceso.
MX349425B (es) Nuevo procedimiento de sintesis del 3-(2-bromo-4,5-dimetoxifenil) propanonitrilo, y aplicacion a la sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.